Lipoprotein effects of different thiazolidinediones in clinical practice

Academic Article

Abstract

  • Objective: To investigate and compare the effects of troglitazone and rosiglitazone on plasma lipoproteins in patients with type 2 diabetes mellitus and dyslipidemia. Methods: This cohort study was conducted in the Diabetes Clinic of the University of Alabama. We identified and studied 18 patients with type 2 diabetes and dyslipidemia first treated with troglitazone (600 mg/day) and then transferred to rosiglitazone therapy (8 mg/day). Results: By lowering insulin resistance, thiazolidinediones have common effects on lipoproteins; however, these drugs may have important differences in their effects on individual lipid particles. In our patients, both troglitazone and rosiglitazone increased low-density lipoprotein (LDL) levels; however, only rosiglitazone significantly changed the LDL particle size to the larger, less atherogenic LDL particle. Similarly, both troglitazone and rosiglitazone increased high-density lipoprotein (HDL) concentrations; however, although troglitazone increased only HDL3, rosiglitazone also significantly increased the larger, more cardioprotective HDL2 particle. Furthermore, only troglitazone increased Lp(a) significantly. In contrast, Conclusion: Small but significant differences exist in the effects of different thiazolidinediones on lipoproteins in patients with type 2 diabetes. Overall, the changes in lipoprotein profile induced by rosiglitazone therapy seem to have less atherogenic potential than those resulting from the use of troglitazone.
  • Authors

    Published In

  • Endocrine Practice  Journal
  • Digital Object Identifier (doi)

    Author List

  • Ovalle F; Bell DSH
  • Start Page

  • 406
  • End Page

  • 410
  • Volume

  • 8
  • Issue

  • 6